List of Tyvaso drug patents

Tyvaso is owned by United Therap.

Tyvaso contains Treprostinil.

Tyvaso has a total of 6 drug patents out of which 0 drug patents have expired.

Tyvaso was authorised for market use on 30 July, 2009.

Tyvaso is available in solution;inhalation dosage forms.

Tyvaso can be used as method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device.

The generics of Tyvaso are possible to be released after 15 December, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US10376525 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation
Mar, 2028

(5 years from now)

US9358240 UNITED THERAP Treprostinil administration by inhalation
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 31, 2024

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 30 July, 2009

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION;INHALATION

How can I launch a generic of TYVASO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in